Breaking News Instant updates and real-time market news.

MRK

Merck

$79.48

-0.55 (-0.69%)

06:54
05/07/19
05/07
06:54
05/07/19
06:54

Merck says Belsomra met primary, secondary efficacy endpoints in Phase 3 trial

Merck announced the presentation of results of a Phase 3 trial evaluating the efficacy and safety of Belsomra C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer's disease dementia. In the trial, Belsomra met its primary and secondary efficacy endpoints. For the primary endpoint, 4-weeks of treatment with Belsomra improved mean total sleep time by 28.2 minutes versus placebo. This corresponded to a mean increase from baseline of 73.4 minutes with Belsomra and a mean increase from baseline of 45.2 minutes with placebo. Adverse events were reported in 22.5% of patients receiving Belsomra compared to 16.1% of those receiving placebo. The results are being presented at the 2019 American Academy of Neurology Annual Meeting, held May 4-10. Belsomra C-IV 5 mg, 10 mg, 15 mg and 20 mg tablets are currently approved in the United States for treatment of insomnia characterized by difficulties with sleep onset and sleep maintenance.

  • 18

    May

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

MRK Merck
$79.48

-0.55 (-0.69%)

03/11/19
WBLR
03/11/19
NO CHANGE
WBLR
Outperform
William Blair sum-of-the-parts analysis yields $19.80 value for Pfenex
The majority of Pfenex (PFNX) investor focus has been placed on lead asset PF708, the therapeutic equivalent product candidate to Forteo, William Blair analyst Andy Hsieh tells investors in a research note, citing his talks with clients. The analyst, however, sees "potential for significant value" from the company's collaboration with Jazz Pharmaceuticals (JAZZ). The deal with Jazz could provide patients with an alternative to Erwinaze/Erwinase, which currently suffers from significant supply constraints, and CRM197, a carrier protein that is incorporated as an adjuvant in several vaccine candidates, including Merck's (MRK) pneumococcal vaccine, V114, Hsieh writes. Based on these royalties, the analyst conducted a sum-of-the-parts analysis for Pfenex based on discounted cash flow, and the resulting net present value yielded a value of $19.80 per share. The stock closed Monday at $4.26. The analyst believes the company's "value-creating" catalysts this year, including milestone payment from Jazz for the successful tech transfer of PF743 and PF745 and the approval of PF708, coupled with his valuation analysis, affirm his bullish thesis. Hsieh believes Pfenex shares offer one of the best risk/reward symmetries in small-cap biotech and reiterates an Outperform rating on the name.
03/13/19
CANT
03/13/19
NO CHANGE
Target $95
CANT
Overweight
Merck opportunity in China is underappreciated, says Cantor Fitzgerald
After taking a deeper look at the Chinese PD-1 market, Cantor Fitzgerald analyst Louise Chen believes it could equate to billions of sales that are not yet in the forecasts for Merck's Keytruda. She thinks the peak sales potential of PD-1s in China remains underappreciated. China's pharma market can grow to $225B by 2025, which would support a growing PD-1/PD-L1 market, Chen tells investors in a research note titled "Deep Dive into China: A Complicated but Underappreciated Opportunity." The analyst keeps an Overweight rating on Merck with a $95 price target.
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
04/24/19
UBSW
04/24/19
NO CHANGE
Target $102
UBSW
Neutral
Procter & Gamble price target raised to $102 from $95 at UBS
UBS analyst Steven Strycula raised his price target on Procter & Gamble (PG) to $102, saying that yesterday's sell-off on investor concerns about the company's ability to boost margin "overlooks" the "upcoming inflection". The analyst keeps his Neutral rating, but notes that the Q3 margin pressure was "transitory" as it was impacted by adverse FX, commodities, higher bonus, and Merck (MRK) integration headwinds.

TODAY'S FREE FLY STORIES

MOMO

Momo

$25.94

-0.72 (-2.70%)

13:35
05/24/19
05/24
13:35
05/24/19
13:35
Options
Momo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 11

    Jun

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

13:34
05/24/19
05/24
13:34
05/24/19
13:34
Recommendations
Alpine Immune Sciences, Adaptimmune, Gilead analyst commentary  »

Alpine Immune Sciences…

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

GILD

Gilead

$66.88

-0.27 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

  • 17

    Jun

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, GILD

Gilead

$66.91

-0.24 (-0.36%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30
Hot Stocks
Alpine Immune Sciences reports notice of termination of license pact with Kite »

In a regulatory filing…

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

GILD

Gilead

$66.91

-0.24 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

NVS

Novartis

$88.00

3.54 (4.19%)

, BIIB

Biogen

$228.00

-1.05 (-0.46%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30
Hot Stocks
ICER says Zolgensma price falls within upper bound of benchmark range »

The Institute for…

NVS

Novartis

$88.00

3.54 (4.19%)

BIIB

Biogen

$228.00

-1.05 (-0.46%)

IONS

Ionis Pharmaceuticals

$65.44

-1.69 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

GOLD

Barrick Gold

$11.93

-0.03 (-0.25%)

, ABGLF

Acacia Mining

$0.00

(0.00%)

13:23
05/24/19
05/24
13:23
05/24/19
13:23
Periodicals
Barrick CEO tells Reuters Acacia bid reflects Tanzania risk »

Barrick Gold (GOLD) CEO…

GOLD

Barrick Gold

$11.93

-0.03 (-0.25%)

ABGLF

Acacia Mining

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
05/24/19
05/24
13:17
05/24/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
05/24/19
05/24
13:16
05/24/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$61.83

0.75 (1.23%)

13:12
05/24/19
05/24
13:12
05/24/19
13:12
Hot Stocks
Cognizant CEO buys 19K shares of company stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 23

    Jun

NFLX

Netflix

$355.84

3.61 (1.02%)

, GOOG

Alphabet

$1,144.00

3.45 (0.30%)

13:08
05/24/19
05/24
13:08
05/24/19
13:08
Hot Stocks
Netflix to release 'Little Black Mirror' episodes on YouTube starting May 26 »

Netflix Latin America…

NFLX

Netflix

$355.84

3.61 (1.02%)

GOOG

Alphabet

$1,144.00

3.45 (0.30%)

GOOGL

Alphabet Class A

$1,148.10

3.22 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 03

    Jun

  • 06

    Jun

  • 19

    Jun

  • 19

    Jun

  • 25

    Jun

  • 27

    Oct

13:07
05/24/19
05/24
13:07
05/24/19
13:07
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 5/24 Baker-Hughes…

UAL

United Continental

$81.10

0.19 (0.23%)

, BA

Boeing

$356.58

6.01 (1.71%)

13:07
05/24/19
05/24
13:07
05/24/19
13:07
Periodicals
United extending Boeing 737 Max cancellations through August 3, CNBC reports »

United Airlines (UAL)…

UAL

United Continental

$81.10

0.19 (0.23%)

BA

Boeing

$356.58

6.01 (1.71%)

AAL

American Airlines

$29.41

-0.08 (-0.27%)

LUV

Southwest

$51.33

0.36 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 12

    Jun

  • 12

    Jun

  • 25

    Jul

  • 13

    Nov

BBY

Best Buy

$64.89

-0.9 (-1.37%)

, SSNLF

Samsung

$0.00

(0.00%)

13:04
05/24/19
05/24
13:04
05/24/19
13:04
Periodicals
Best Buy cancels preorders for Samsung's foldable phone, CNN reports »

Best Buy (BBY) is…

BBY

Best Buy

$64.89

-0.9 (-1.37%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 11

    Jun

BHGE

Baker Hughes

$22.28

-0.78 (-3.38%)

13:03
05/24/19
05/24
13:03
05/24/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 983 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$162.59

1.07 (0.66%)

13:02
05/24/19
05/24
13:02
05/24/19
13:02
Hot Stocks
Visa CFO Vasant Prabhu appointed company vice chairman »

Visa announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

EHC

Encompass Health

$59.22

-0.315 (-0.53%)

13:01
05/24/19
05/24
13:01
05/24/19
13:01
Hot Stocks
Encompass Health names Kim Sullivan chief human resources officer »

Encompass Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

IONS

Ionis Pharmaceuticals

$67.35

0.215 (0.32%)

, BIIB

Biogen

$229.80

0.75 (0.33%)

13:01
05/24/19
05/24
13:01
05/24/19
13:01
Hot Stocks
Ionis, Biogen slip after FDA approves Novartis' Zolgensma for SMA treatment »

Shares of Ionis…

IONS

Ionis Pharmaceuticals

$67.35

0.215 (0.32%)

BIIB

Biogen

$229.80

0.75 (0.33%)

NVS

Novartis

$87.21

2.75 (3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

XRT

S&P Retail Index SPDR

$41.58

-0.09 (-0.22%)

13:00
05/24/19
05/24
13:00
05/24/19
13:00
Options
Size four-way put spread in SPDR Retail Trust as shares extend losses »

Size four-way put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGNX

Regenxbio

$43.60

1.11 (2.61%)

, NVS

Novartis

$87.13

2.67 (3.16%)

12:53
05/24/19
05/24
12:53
05/24/19
12:53
Hot Stocks
Regenxbio up 6% after Novartis receives FDA approval for Zolgensma »

Regenxbio (RGNX) will…

RGNX

Regenxbio

$43.60

1.11 (2.61%)

NVS

Novartis

$87.13

2.67 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

NVS

Novartis

$87.04

2.58 (3.05%)

12:47
05/24/19
05/24
12:47
05/24/19
12:47
Hot Stocks
Novartis says wholesale acquisition cost of Zolgensma $2.125M »

AveXis, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TIVO

TiVo

$6.87

0.04 (0.59%)

12:45
05/24/19
05/24
12:45
05/24/19
12:45
Options
TiVo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

12:45
05/24/19
05/24
12:45
05/24/19
12:45
General news
Breaking General news story  »

Week of 5/24 Baker-Hughes…

VWAGY

Volkswagen

$0.00

(0.00%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Appeals court rules in favor of Volkswagen diesel car owners, Reuters reports »

A German appeals court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$56.30

0.85 (1.53%)

, WCG

WellCare

$267.57

-6.89 (-2.51%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Third Point confirms Centene stake to CNBC, says WellCare deal in best interest »

CNBC tweeted: "Third…

CNC

Centene

$56.30

0.85 (1.53%)

WCG

WellCare

$267.57

-6.89 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

, IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

12:40
05/24/19
05/24
12:40
05/24/19
12:40
Technical Analysis
On The Fly: ETF fund flow highlights »

Flows for the past week…

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

XLK

Technology Select Sector SPDR

$73.62

0.33 (0.45%)

SMH

Market Vectors Semiconductor

$100.37

0.23 (0.23%)

SOXX

iShares PHLX Semiconductor ETF

$180.13

0.06 (0.03%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$119.60

0.14 (0.12%)

EEM

iShares MSCI Emerging Markets ETF

$40.00

0.08 (0.20%)

XLU

Utilities SPDR

$59.99

0.07 (0.12%)

XLV

Health Care Select Sector SPDR

$89.56

0.17 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$126.65

0.46 (0.36%)

, CCOEY

Capcom

$0.00

(0.00%)

12:37
05/24/19
05/24
12:37
05/24/19
12:37
Hot Stocks
Microsoft says Project xCloud can stream more than 3,500 games »

Kareem Choudhry,…

MSFT

Microsoft

$126.65

0.46 (0.36%)

CCOEY

Capcom

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 23

    Jun

  • 06

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.